AKT1 and breast carcinoma: Given that new combinations of the inhibitors of the PI3K/AKT/mTOR signaling pathway could provide a new perspective for the management of breast cancers, especially for the cases with precision medicine and drug resistance, future work is need to explore the therapeutic potential and safety profile of mTORC1 inhibitors (e.g., everolimus, temsirolimus and ridaforolimus), mTORC1/2 inhibitors (e.g., vistusertib), as well as AKT inhibitors (e.g., ipatasertib) monotherapy and in combination with ICI.